These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 10721171)

  • 1. Interferon-alpha-2b + ribavirin for the treatment of chronic hepatitis C in non-responders to interferon-alpha-monotherapy.
    Tromm A; Greving I; Griga T; Mankel K; Hüppe D
    Z Gastroenterol; 2000 Feb; 38(2):159-64. PubMed ID: 10721171
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis C in patients who failed interferon monotherapy: effects of higher doses of interferon and ribavirin combination therapy. The Virginia Cooperative Hepatitis Treatment Group.
    Shiffman ML; Hofmann CM; Gabbay J; Luketic VA; Sterling RK; Sanyal AJ; Contos MJ; Ryan MJ; Yoshida C; Rustgi V
    Am J Gastroenterol; 2000 Oct; 95(10):2928-35. PubMed ID: 11051370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study.
    Barbaro G; Di Lorenzo G; Soldini M; Giancaspro G; Bellomo G; Belloni G; Grisorio B; Annese M; Bacca D; Francavilla R; Rizzo G; Barbarini G
    Am J Gastroenterol; 1998 Dec; 93(12):2445-51. PubMed ID: 9860407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.
    Teuber G; Berg T; Hoffmann RM; Leifeld L; Lafrenz M; Spengler U; Pape GR; Hopf U; Zeuzem S
    Digestion; 2000; 61(2):90-7. PubMed ID: 10705172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial.
    Sostegni R; Ghisetti V; Pittaluga F; Marchiaro G; Rocca G; Borghesio E; Rizzetto M; Saracco G
    Hepatology; 1998 Aug; 28(2):341-6. PubMed ID: 9695995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone.
    Min AD; Jones JL; Esposito S; Lebovics E; Jacobson IM; Klion FM; Goldman IS; Geders JM; Tobias H; Bodian C; Bodenheimer HC
    Am J Gastroenterol; 2001 Apr; 96(4):1143-9. PubMed ID: 11316161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pattern of response to interferon alpha (alpha-IFN) predicts sustained response to a 6-month alpha-IFN and ribavirin retreatment for chronic hepatitis C. TVVH Study Group.
    Cavalletto L; Chemello L; Donada C; Casarin P; Belussi F; Bernardinello E; Marino F; Pontisso P; Gatta A; Alberti A
    J Hepatol; 2000 Jul; 33(1):128-34. PubMed ID: 10905596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon alpha-2b in combination with ribavirin for the treatment of chronic hepatitis C: assessment of virological, biochemical and histological treatment response.
    Petrenkiene V; Gudinaviciene I; Jonaitis L; Kupcinskas L
    Medicina (Kaunas); 2004; 40(6):538-46. PubMed ID: 15208476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.
    Kallinowski B; Liehr H; Moeller B; Stremmel W; Wechsler JG; Wiese M; Goeser T
    Z Gastroenterol; 2001 Mar; 39(3):199-204, 206. PubMed ID: 11324136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of pegylated interferon alpha 2b and ribavirin in chronic hepatitis C--a report from eastern India.
    Ray G; Pal S; Nayyar I; Dey S
    Trop Gastroenterol; 2007; 28(3):109-12. PubMed ID: 18383998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily interferon induction regimen using different manufactured interferons (alpha-2A or alpha-2B) in combination with ribavirin for treatment of chronic hepatitis C: a prospective randomized study.
    Braga EL; Lyra AC; Nascimento L; Netto E; Kalabrik L; Lyra LG
    Arq Gastroenterol; 2006; 43(4):275-9. PubMed ID: 17406754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-four vs. forty-eight weeks of re-therapy with interferon alpha 2b and ribavirin in interferon alpha monotherapy relapsers with chronic hepatitis C.
    August-Jörg BS; Borovicka J; Dufour JF; Gonvers JJ; Henz S; Hermann R; Meyenberger C; Weitz M; Renner EL;
    Swiss Med Wkly; 2003 Aug; 133(33-34):455-60. PubMed ID: 14625812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized trial of high-dose interferon alpha-2b, with or without ribavirin, in chronic hepatitis C patients who have not responded to standard dose interferon.
    Malik AH; Kumar KS; Malet PF; Ostapowicz G; Adams G; Wood M; Yarbrough K; Jones A; Lee WM
    Aliment Pharmacol Ther; 2002 Mar; 16(3):381-8. PubMed ID: 11876690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alfa alone versus interferon alfa and ribavirin.
    Ahmad J; Dodson SF; Demetris AJ; Fung JJ; Shakil AO
    Liver Transpl; 2001 Oct; 7(10):863-9. PubMed ID: 11679984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
    de Lédinghen V; Trimoulet P; Winnock M; Bernard PH; Bourlière M; Portal I; Rémy AJ; Szostak N; Lévy S; Tran A; Abergel A; Chêne G; Fleury H; Couzigou P;
    J Hepatol; 2002 Jun; 36(6):819-26. PubMed ID: 12044534
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple antiviral re-therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine in nonresponders to interferon-alpha and ribavirin.
    Zilly M; Lingenauber C; Desch S; Väth T; Klinker H; Langmann P
    Eur J Med Res; 2002 Apr; 7(4):149-54. PubMed ID: 12010649
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Is combination therapy of chronic hepatitis C with interferon alpha and ribavirin in primary interferon nonresponders indicated?--An analysis of personal experiences and review of the literature].
    Wedemeyer H; Jäckel E; Wedemeyer J; Frank H; Schüler A; Trautwein C; Manns MP
    Z Gastroenterol; 1998 Sep; 36(9):819-27. PubMed ID: 9795411
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
    Jacobson IM; Ahmed F; Russo MW; Lebovics E; Dieterich DT; Esposito SP; Bach N; Klion F; Tobias H; Antignano L; Brown RS; Gabbaizadeh D; Geders J; Levendoglu H
    Am J Gastroenterol; 2004 Sep; 99(9):1700-5. PubMed ID: 15330905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?].
    Stránský J; Rýzlová M; Stríteský J; Nĕmecek V
    Cas Lek Cesk; 2002 Jun; 141(11):351-4. PubMed ID: 12099059
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-antibodies and the breakthrough phenomenon during ribavirin/interferon-alpha combination therapy and interferon-alpha monotherapy of patients with chronic hepatitis C.
    Hoffmann RM; Berg T; Teuber G; Prümmer O; Leifeld L; Jung MC; Spengler U; Zeuzem S; Hopf U; Pape GR
    Z Gastroenterol; 1999 Aug; 37(8):715-23. PubMed ID: 10494606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.